Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
Andreas Hochhaus(Klinikum Magdeburg), Giuseppe Saglio(University of Turin), Timothy P. Hughes(South Australian Health and Medical Research Institute), Richard A. Larson(University of Chicago), D-W Kim(Catholic University of Korea), Surapol Issaragrisil(Siriraj Hospital), Philipp D. le Coutre(Charité - Universitätsmedizin Berlin), Gabriel Étienne(Institut Bergonié), P.E. Dorlhiac‐Llacer(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Richard E. Clark(University of Liverpool), Ian W. Flinn(Sarah Cannon), Hirohisa Nakamae(Osaka City University), Breanne Donohue(Novartis (United States)), Weiping Deng(Novartis (United States)), Darshan Dalal(Novartis (United States)), Hans D. Menssen(Novartis (Switzerland)), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center)
Cited by 849Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis